Outset Medical (OM)
(Delayed Data from NSDQ)
$0.71 USD
-0.01 (-0.95%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.71 0.00 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Outset Medical, Inc. (OM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.46 | $6.00 | $0.50 | 380.56% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Outset Medical, Inc. comes to $3.46. The forecasts range from a low of $0.50 to a high of $6.00. The average price target represents an increase of 380.56% from the last closing price of $0.72.
Analyst Price Targets (7 )
Broker Rating
Outset Medical, Inc. currently has an average brokerage recommendation (ABR) of 2.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.13 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 37.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 37.5%, while Buy represented 25%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/OM.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 2 | 2 | 1 |
Hold | 3 | 3 | 2 | 2 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.25 | 2.25 | 2.13 | 2.13 | 2.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Not Identified | Not Identified | Moderate Buy | Hold |
8/8/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
8/8/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Hold | Hold |
4/8/2024 | BTIG | Marie Thibault | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.25 |
ABR (Last week) | 2.25 |
# of Recs in ABR | 8 |
Average Target Price | $3.46 |
LT Growth Rate | 25.10% |
Industry | Medical Info Systems |
Industry Rank by ABR | 63 of 253 |
Current Quarter EPS Est: | -0.42 |